ライフサイエンスコーパス: passive immunotherapy

1 provide a new insight for the development of passive immunotherapy.

2 r therapeutic intervention through augmented passive immunotherapy.

3 east cancer, a number of concerns exist with passive immunotherapy.

4 sition to evaluate the effects of anti-Abeta passive immunotherapy.

5 roles against malignancy in both active and passive immunotherapy.

6 nous IgG or monoclonal antibody cocktail for passive immunotherapy.

7 led to their production and optimization for passive immunotherapy.

8 ed to be a complete summary of all trials of passive immunotherapy.

9 resent attractive targets for vaccination or passive immunotherapy.

10 ent with conventional active vaccination and passive immunotherapy.

11 their levels, such as secretase inhibitors, passive immunotherapy against Abeta and mGluR5 antagonis

12 K should be further explored as a target for passive immunotherapy against complicated S. aureus infe

13 Passive immunotherapy against HIV-1 will most likely req

14 NA represents a viable delivery platform for passive immunotherapy against HIV-1 with expansion to a

15 e is an urgent need for the development of a passive immunotherapy against the category B select agen

16 monoclonals can be potential candidates for passive immunotherapy and for guiding immunogen design.

17 ding mutations in the hE16 epitope to resist passive immunotherapy and for the selection of neutraliz

18 s study was to assess the clinical effect of passive immunotherapy and its heterogeneity according to

19 More than ten new approaches to active and passive immunotherapy are under investigation in clinica

20 These findings have implications for passive immunotherapy as an approach toward controlling

21 , it suggests that the beneficial effects of passive immunotherapy by Bin1 mAb in UC treatment may be

22 ned the outcome of mice treated with anti-AB passive immunotherapy by exacerbating the deposition of

23 The results indicate that passive immunotherapy can accelerate elimination of HIV-

24 These results suggest that early passive immunotherapy can eliminate early viral foci and

25 Development of similar passive immunotherapy could also be especially important

26 rulence factor for R. oryzae, and anti-Ftr1p passive immunotherapy deserves further evaluation as a s

27 Our results show that passive immunotherapy during acute SHIV infection differ

28 become an attractive alternative target for passive immunotherapy efforts for Alzheimer's disease (A

29 global emergency due to SARS-CoV-2 outbreak, passive immunotherapy emerges as a promising treatment f

30 e greatest promise for generating active and passive immunotherapies for treating overdose or addicti

31 provide a safer therapeutic alternative for passive immunotherapy for AD.

32 t into the mechanism of action of a specific passive immunotherapy for AD.

33 we analyzed various scenarios for effective passive immunotherapy for AD.

34 isease-modifying, anti-amyloid beta-directed passive immunotherapy for Alzheimer's disease, questions

35 orum quenching vaccines for use in active or passive immunotherapy for prevention or treatment of S.

36 Here we report for the first time on passive immunotherapy for Tau in two well established tr

37 hese data cast further doubt on the value of passive immunotherapy for the treatment of EBOV infectio

38 Passive immunotherapy for treatment or prophylaxis of HI

39 complex class I and II molecules, active and passive immunotherapy has moved to center stage once aga

40 can be used to predict the effectiveness of passive immunotherapies in mouse models.

41 he efficacy of treatment with mAbs and other passive immunotherapies in patients hospitalized with se

42 es as a more optimal and flexible choice for passive immunotherapy in burn wound infections.

43 Moreover, the success of passive immunotherapy in small-animal models suggests th

44 fection is frequently cited as evidence that passive immunotherapy is a viable treatment option.

45 Passive immunotherapy is an approved method used to prot

46 Thus, passive immunotherapy is effective at preventing the bui

47 However, such passive immunotherapy is unlikely to maintain memory T c

48 mmune plasma demonstrates the feasibility of passive immunotherapy, it is limited in quantity, variab

49 lso show that targeting these oligomers with passive immunotherapy leads to some improvement in motor

50 rus infection and raise the possibility that passive immunotherapy may be useful in HCPS.

51 Passive immunotherapy might be a useful treatment option

52 phorylation and then neuritic dystrophy, but passive immunotherapy mitigates this.

53 study, an ovine antibody-based platform for passive immunotherapy of C. difficile infection is descr

54 17-1A and GA733, has been a useful target in passive immunotherapy of CRC patients with mAb and in ac

55 basophil activation and might be useful for passive immunotherapy of grass pollen allergy.

56 l antibodies (MAbs) are being considered for passive immunotherapy of HIV-1 infection.

57 e developed against Shiga toxin 1 (Stx1) for passive immunotherapy of HUS.

58 y have important implications for active and passive immunotherapy of prostate and other cancers.

59 ssociated micro-hemorrhages, i.c.v.-targeted passive immunotherapy offers a promising therapeutic app

60 imaging was employed to study the effects of passive immunotherapies on lethality and viral dissemina

61 Passive immunotherapy (PI) is being explored as a potent

62 Both active and passive immunotherapy protocols decrease insoluble amylo

63 a possible explanation of why adoptive (i.e. passive) immunotherapy protocols can sometimes actually

64 Passive immunotherapy provided 100% and 40% protection i

65 evaluate the potential efficacy of active or passive immunotherapy regimens as adjunctive treatments.

66 clinical trials are ongoing using active and passive immunotherapy targeting the amyloid-beta (Abeta)

67 (FDA) approval, and there are several other passive immunotherapies that hold promise as therapeutic

68 ently, ~16% of participants in an anti-Abeta passive immunotherapy trial for mild-to-moderate Alzheim

69 Passive immunotherapies using monoclonal antibodies for

70 Passive immunotherapy using fibril-reactive mAbs has bee

71 Therefore, passive immunotherapy using monoclonal antibodies is now

72 logical tau oligomers in aged Tg2576 mice by passive immunotherapy using tau oligomer-specific monocl

73 F4 can be used to identify AL candidates for passive immunotherapy using the chimeric form of the ant

74 uccessful attempts spanning several decades, passive immunotherapies utilizing monoclonal antibodies

75 ing through the B-cell and T-cell receptors; passive immunotherapies utilizing these receptors, such

76 of llama-derived single chain nanobodies for passive immunotherapy was considered attractive.

77 Vectored passive immunotherapy with an anti-tau monoclonal antibo

78 The mainstay of prophylaxis has been passive immunotherapy with hepatitis B immune globulin (

79 Alzheimer's disease (AD) patients treated by passive immunotherapy with humanized anti-amyloid beta m

80 Despite the success of passive immunotherapy with monoclonal antibodies (mAbs),

81 ough there is no effective treatment for AD, passive immunotherapy with monoclonal antibodies against

82 Passive immunotherapy with monoclonal antibodies has imp

83 Passive immunotherapy with monoclonal antibodies is an i

84 fied as being farthest along in development; passive immunotherapy with monoclonal antibodies, postex

85 Among these strategies is passive immunotherapy with monoclonal antibody, alone or

86 Passive immunotherapy with RG-1 was protective in mice.

87 vide "proof of principle" for the ability of passive immunotherapy with rituximab to elicit an active

88 Although passive immunotherapy with these Abs are approved for tr

89 MAbs may provide the most effective form of passive immunotherapy, with the caveat that these may de